Skip to main content

Day: November 24, 2023

OZOP Plus Engages TecAssured to Provide Direct to Consumer Electric Vehicle Service Contracts

Warwick, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) — EV Insurance Company, Inc, DBA OZOP Plus, a wholly owned subsidiary of Ozop Energy Solutions, Inc. (OZSC), announces a collaboration with TecAssured LLC, a leading software company renowned for its cutting-edge technology solutions in the comprehensive lifecycle management. TecAssured’s prowess in developing innovative solutions for service contracts, warranties, and aftermarket products across diverse industries is set to elevate OZOP Plus’s offerings to new heights. Their robust rating engine, streamlined administration software, online sales portals, and direct-to-consumer eContracting websites, provide customizable and out-of-the-box solutions that empower companies nationwide. In a strategic move poised to reshape the market, OZOP Plus is set to unveil its’ OZOP Plus...

Continue reading

Rail Vision Announces Third Quarter 2023 Financial Results

RA’ANANA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), a development stage technology company seeking to revolutionize railway safety and the data-related market, today reported financial results for the third quarter ended September 30, 2023. Shahar Hania, CEO of Rail Vision, stated, “I would like to begin by expressing our heartfelt sympathies and condolences to all those who have been affected by the recent tragic events in Israel. Despite the difficult circumstances in our home country, I want to reassure our shareholders and stakeholders that Rail Vision’s operations continue unabated. Our commitment to delivering innovative, safety-enhancing technology to the global rail industry remains as strong as ever.” “We reached another significant milestone in the...

Continue reading

Versus Systems Announces Strategic Investment from Cronus Equity Capital Group, LLC

LOS ANGELES, Nov. 24, 2023 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) announced today that the Company recently secured a strategic investment (the “Investment”) from Cronus Equity Capital Group, LLC (“CECG”). The Investment contemplates the issuance of up to 24,727,361 common shares of Versus to CECG representing approximately 51% of the Company’s issued and outstanding common shares of which 15,838,441 common shares (the “First Tranche) were issued to CECG on November 22, 2023 and a further 8,888,920 common shares (the “Second Tranche”) are expected to be issued to CECG next week. Per the terms of the agreement, CECG purchased the First Tranche at a price of $0.1618 per share, representing a premium to the five-day average Nasdaq Official Closing Price of $0.1578 per share, for a total USD...

Continue reading

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene

TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray PowderTING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray PowderTARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) — Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredient in any Ting® Antifungal Spray products, the review showed that unexpected levels of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal...

Continue reading

Global Mofy Metaverse Limited and ELLE CHINA, ELLE MEN CHINA Unite for a Dynamic Partnership, Redefining the Art of Advertising

Beijing, CHINA, Nov. 24, 2023 (GLOBE NEWSWIRE) — Global Mofy Metaverse Limited (the “Company” or “Global Mofy Metaverse”) (NASDAQ: GMM), a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry, today announced the Company and ELLE CHINA, ELLE MEN CHINA have forged a long-term partnership, embarking on an eagerly anticipated collaboration that promises mutual promotional benefits and an array of exciting projects in the realm of advertising and beyond. As part of this collaboration, ELLE MEN CHINA will provide Global Mofy Metaverse with a stable and influential platform for publicity, including avenues such as video channels and websites. These platforms will grant Global Mofy Metaverse invaluable exposure, enabling the dissemination...

Continue reading

Safety Shot Continues Scientific Development with Double-Blind Placebo-Controlled Trial Designed to Assess the Effects of Safety Shot on Blood and Breath Alcohol Levels

Topline data expected Q1 2024 Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and improving clarity A double-blinded, placebo controlled, clinical trial designed to compare the effects of Safety shot on blood and breath alcohol levels is underway.JUPITER, FL, Nov. 24, 2023 (GLOBE NEWSWIRE) — Safety Shot, Inc. (Nasdaq: SHOT) today announced that a clinical trial to measure the effects of Safety Shot on blood and breath alcohol has commenced. Safety Shot is the first patented beverage that helps people feel better faster by reducing blood alcohol content and boosting clarity. Created by industry experts and validated by research, Safety Shot is a nutraceutical functional beverage that accelerates the body’s break-down of alcohol while aiding in recovery and rehydration. While there are many...

Continue reading

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended September 30, 2023. “I am pleased to report that we have reached a new pivotal point for our proprietary ExoPTEN drug, primarily in advancing our United States Food and Drug Administration regulatory strategy and the commercialization of our exosome-based technology portfolio,” said Dr. Lior Shaltiel, CEO of NurExone. “Most notably, we have received Orphan-Drug Designation and completed our Pre- Investigational New Drug meeting with the United States Food and Drug Administration for our ExoPTEN drug, which potentially expedites the process of launching our first ExoTherapy...

Continue reading

Black Friday and Cyber Monday: Get the Mudra Band for Apple Watch with Exclusive Holiday Offer!

Celebrate the future of gesture control– Shop Now at: www.mudra-band.com  YOKNEAM ILLIT, ISRAEL, Nov. 24, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in AI-powered touchless sensing wearables, is excited to announce a special Black Friday and Cyber Monday offer for its highly anticipated Mudra Band for Apple Watch, available now for orders at www.mudra-band.com. This innovative accessory, designed to revolutionize the way we interact with our Apple devices, is offered at an exclusive unbeatable price for the holiday shopping weekend.   The Mudra Band is an AI-powered aftermarket accessory that connects to the Apple Watch and uses wrist neural signals to translate movement intent into digital command. Unleash the full potential...

Continue reading

New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder

TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD) symptoms in children. SciSparc’s novel SCI-210 therapy is not only a medication based on CBD; it is also a unique combination of cannabidiol (CBD) and SciSparc’s proprietary Palmitoylethanolamide, aimed to ease the symptoms of ASD. How will it work? Over a period of 20 weeks, the trial will enroll 60 participants between the ages of 5-18 years old to scientifically measure how SCI-210 compares...

Continue reading

Rogers Sugar Seeks Mediation in Ongoing Effort to Reach Fair Collective Agreement with Workers at Vancouver Refinery

VANCOUVER, British Columbia, Nov. 24, 2023 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (the “Company” or “Rogers Sugar”) (TSX: RSI) today announced that it has applied to the British Columbia Labour Relations Board for mediation to reach a fair collective agreement with the Public and Private Workers of Canada (PPWC) Local 8 representing workers at the Company’s Vancouver refinery, and that the union has accepted mediation. The Company provided the following statement: “Rogers Sugar looks forward to the opportunity to work constructively with the union toward a fair collective agreement that will return our Vancouver plant to full sugar production as soon as possible. We remain fully committed to engaging in discussions aimed at finding a solution that works for the Company and for employees, and one that supports customers for the short...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.